Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) – Investment analysts at William Blair dropped their Q3 2023 earnings per share (EPS) estimates for shares of Maravai LifeSciences in a report issued on Tuesday, August 8th. William Blair analyst M. Larew now expects that the company will post earnings of ($0.02) per share for the quarter, down from their prior forecast of $0.06. The consensus estimate for Maravai LifeSciences’ current full-year earnings is $0.15 per share. William Blair also issued estimates for Maravai LifeSciences’ Q4 2023 earnings at $0.00 EPS, FY2023 earnings at ($0.04) EPS and FY2024 earnings at ($0.05) EPS.
Other research analysts also recently issued reports about the company. Royal Bank of Canada dropped their price objective on Maravai LifeSciences from $20.00 to $18.00 and set an “outperform” rating on the stock in a research note on Tuesday. Credit Suisse Group dropped their price target on Maravai LifeSciences from $14.00 to $11.00 and set a “neutral” rating on the stock in a research note on Tuesday. Morgan Stanley dropped their price target on Maravai LifeSciences from $27.00 to $12.00 and set an “overweight” rating on the stock in a research note on Wednesday. 58.com reaffirmed a “downgrade” rating on shares of Maravai LifeSciences in a research note on Tuesday, May 23rd. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Maravai LifeSciences from $23.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $14.10.
Maravai LifeSciences Stock Up 0.4 %
Shares of NASDAQ:MRVI opened at $10.34 on Friday. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of 18.14 and a beta of -0.26. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.33 and a quick ratio of 5.69. The business’s 50-day moving average is $12.48 and its 200-day moving average is $13.52. Maravai LifeSciences has a 1 year low of $9.20 and a 1 year high of $27.15.
Institutional Trading of Maravai LifeSciences
Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank Julius Baer & Co. Ltd Zurich raised its stake in shares of Maravai LifeSciences by 97,363.1% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 213,619,721 shares of the company’s stock worth $2,655,293,000 after purchasing an additional 213,400,541 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Maravai LifeSciences by 32.6% in the first quarter. Thrivent Financial for Lutherans now owns 8,189,798 shares of the company’s stock valued at $114,739,000 after acquiring an additional 2,011,683 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Maravai LifeSciences by 2.2% in the first quarter. BlackRock Inc. now owns 5,899,915 shares of the company’s stock valued at $82,658,000 after acquiring an additional 126,007 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Maravai LifeSciences by 9.1% in the fourth quarter. JPMorgan Chase & Co. now owns 3,911,032 shares of the company’s stock valued at $55,967,000 after acquiring an additional 326,260 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Maravai LifeSciences by 39.8% in the second quarter. Mackenzie Financial Corp now owns 3,546,386 shares of the company’s stock valued at $44,117,000 after acquiring an additional 1,008,824 shares in the last quarter. 50.62% of the stock is owned by hedge funds and other institutional investors.
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
- Five stocks we like better than Maravai LifeSciences
- How to Invest in Canada for Beginners
- Investing in Coffee: 3 Great Strategies to Consider
- Investing in Agriculture 101: How to Invest in Agriculture
- 5 Best Stocks to Buy in a Bear Market
- How to Read Stock Charts for Beginners
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
